Three cancer drugs separately earned FDA approval: The KRAS inhibitor sotorasib (Lumakras; Amgen) was approved for use with the EGFR inhibitor panitumumab (Vectibix; Amgen) to treat patients with ...

1Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.

3Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. *Corresponding Author: David A. Reardon, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.

1Northwestern University, Chicago, Illinois.

NCI Director W. Kimryn Rathmell, MD, PhD, announced today that she will step down effective Monday, January 20, the same day Donald Trump will be inaugurated as president. Rathmell, who had previously ...

1Division of Solid Tumor Oncology, Memorial Sloan Kettering, New York, New York. *Corresponding Author: Luis A. Diaz Jr, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. E ...

1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

1Combination Strategies for Translational Immunotherapy, Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra, Pamplona, Spain. 2Department of ...

Although it has risen from 7% over the past decade, the relative 5-year survival rate for pancreatic cancer is 13%, the same rate as reported last year, according to the just released American Cancer ...

Major Finding: Elevated bile acids (BA) in liver cancer contribute to T-cell dysfunction. Concept: BA accumulation in T cells promotes ER stress, reducing effector function and viability. Impact: ...

1The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 2Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.